Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (381-390 of 560) with videos related to

Pageof 56
Sort By:
Critical Reviews in Oncology/Hematology|April 8, 2022
Immunotherapy for head and neck cancer: Present and futureMorena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
ESMO Open|September 27, 2019
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational studyRaimondo Di Liello, Vincenza Ciaramella, Giusi Barra, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Annals of Surgical Oncology|July 28, 2022
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORxOlga Kantor, Harold J Burstein, Tari A King, et al.
Cancer|October 6, 2021
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudySofia F Garcia, Robert J Gray, Joseph A Sparano, et al.
Science Immunology|September 2, 2022
Embryonic and neonatal waves generate distinct populations of hepatic ILC1sColin Sparano, Darío Solís-Sayago, Anjali Vijaykumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupAmye J Tevaarwerk, Molin Wang, Fengmin Zhao, et al.
Blood Advances|December 22, 2018
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomasErin G Reid, David Looney, Frank Maldarelli, et al.
Pageof 56

Showing results (381-390 of 560) with videos related to

Sort By:
Pageof 56
Critical Reviews in Oncology/Hematology|April 8, 2022
Immunotherapy for head and neck cancer: Present and futureMorena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
ESMO Open|September 27, 2019
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational studyRaimondo Di Liello, Vincenza Ciaramella, Giusi Barra, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Annals of Surgical Oncology|July 28, 2022
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORxOlga Kantor, Harold J Burstein, Tari A King, et al.
Cancer|October 6, 2021
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudySofia F Garcia, Robert J Gray, Joseph A Sparano, et al.
Science Immunology|September 2, 2022
Embryonic and neonatal waves generate distinct populations of hepatic ILC1sColin Sparano, Darío Solís-Sayago, Anjali Vijaykumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupAmye J Tevaarwerk, Molin Wang, Fengmin Zhao, et al.
Blood Advances|December 22, 2018
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomasErin G Reid, David Looney, Frank Maldarelli, et al.
Pageof 56